Loading
A phase 1 trial of FX-111 run by Flare Therapeutics Inc., now recruiting.
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer is a phase 1 interventional study registered as NCT07719361 by Flare Therapeutics Inc., with 60 participants planned, started 2026-07-01, primary completion expected 2028-02-15. Conditions recorded: Metastatic Castration Resistant Prostate Cancer, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, mCRPC or Advanced/Metastatic Solid Tumors, mCRPC, Metastatic Castration Resistant Prostate Cancer, Neoplasms Prostate, Neoplasms of Prostate. Interventions recorded: FX-111.
Shares Flare Therapeutics and the tag pipeline.
Shares Flare Therapeutics and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/